<DOC>
	<DOCNO>NCT01968031</DOCNO>
	<brief_summary>This study ass efficacy safety oral Istradefylline ( KW-6002 ) patient moderate severe Parkinson 's Disease . While study , participant continue take usual , prescribed , stable regimen Levodopa/Carbidopa Levodopa/Benserazide therapy plus adjunct Parkinson 's medication . Patients randomize 1:1:1 receive either Istradefylline 20 mg per day , Istradefylline 40 mg per day equivalent placebo . Patients treat 12 week period demonstrate effectiveness Istradefylline improve Parkinson 's disease symptom ( referred improvement patient OFF time ) Istradefylline acceptable safety profile group .</brief_summary>
	<brief_title>A 12-week Randomized Study Evaluate Oral Istradefylline Subjects With Moderate Severe Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Istradefylline</mesh_term>
	<criteria>30 year age old . UK Parkinson 's Disease Society ( UKPDS ) brain bank criterion ( Step 1 2 ) PD PD Stages 24 ON state Modified Hoehn Yahr Scale . On levodopa therapy least 1 year beneficial clinical response baseline visit Taking least 400mg levodopa combination daily stable regimen antiParkinsonian drug ( MAOB , COMT , DA ) least 2 week prior randomization Stable dopaminergic regimen least 4 week immediately prior randomization Documented endofdose wearingoff levodopainduced dyskinesia Have average two hour OFF time per day Subjects apomorphine and/or dopamine receptor antagonist direct gastrointestinal levodopa infusion . Subject neurosurgical operation PD Subjects take A2a antagonist , potent CYP3A4 inhibitor , potent CYP34A inducer Subjects smoke &gt; 5 cigarettes/day</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Moderate Severe Parkinson 's Disease</keyword>
</DOC>